- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference, Kosj Yamoah presents on who needs early salvage RT and who needs adjuvant RT in 2022. Biographies: Kosj Yamoah, MD, Ph.D., Section Head, Genitourinary Radiation Oncology, Director, Radiation Oncology Center Health Disparities Research, Moffitt Cancer Center, Tampa, Florida USA. Related Content: APCCC 2022: Who Needs Early Salvage RT and Wh...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference, Darren Poon presents the management of clinical N1 prostate cancer (including systemic therapy). Biographies: Darren Poon, Comprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, The Chinese University of Hong Kong, Hong Kong Related Content: APCCC 2022: Management of Clinical N1 Prostate Cancer (Including Systemic Therapy) Read th...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference, Nicolas Mottet presents why we are not ready to change management based on next-generation imaging. Biographies: Nicolas Mottet, MD, PhD, University Hospital St. Etienne, St. Etienne, France Related Content: APCCC 2022: Are We Ready to Change Management Based on Next-Generation Imaging? NO Read the Full Video Transcript {article id="138834...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference, Jason Efstathiou presents why we are ready to change management based on next-generation imaging. Biographies: Jason Efstathiou, MD, Radiation Oncologist Professor of Radiation Oncology, Harvard Medical School, Vice-Chair, Faculty & Academic Affairs, and Director, Genitourinary Service, Department of Radiation Oncology, Clinical Co-Directo...
|
- Details
- Kosj Yamoah joins Alicia Morgans in discussing a gray area in the management of biochemical recurrence. Kosj Yamoah presented on who needs early salvage radiotherapy and who needs adjuvant radiotherapy at the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Meeting. The APCCC addresses key areas of prostate cancer management where there are uncertainties or areas where there is a lack of...
|
- Details
- Alicia Morgans speaks with Elena Castro and Colin Pritchard about the evolving role of molecular testing in treating men with prostate cancer. The discussion centers on the challenges and opportunities presented by recent data, particularly concerning combination therapies like Abiraterone and Olaparib. Dr. Pritchard emphasizes the importance of biomarkers in targeted therapies, while also acknowl...
|
- Details
- Alicia Morgans is joined by Drs Fred Saad, Charles Ryan, and Tomasz Beer at the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) in Lugano, Switzerland, to discuss holistic treatment of men with prostate cancer who are being treated with ADT. Dr. Ryan discusses the lack of data on the treatment of depression in men on hormone therapy. Dr. Saad discusses the need to be aware of the patien...
|
- Details
- In this conversation with Alicia Morgans, Bertrand Tombal discusses de-escalation treatment strategies in the management of metastatic hormone-sensitive prostate cancer (mHSPC). They discuss treatment optimization, and how we candefine the minimal dose or duration of a treatment to achieve similar efficacy while preserving quality of life, decreasing side effects, and decreasing resource utilizati...
|
- Details
- In a discussion on the management of metastatic hormone-sensitive prostate cancer (mHSPC) Karim Fizazi joins Alicia Morgans in discussing when low-volume disease on conventional imaging becomes high-volume on next-generation imaging in mHSPC. Biographies: Karim Fizazi, MD, Ph.D., is a medical oncologist at Gustave Roussy, and a full professor in Oncology at the University of Paris-Saclay in Villej...
|
- Details
- Elena Castro and Joaquin Mateo join Alicia Morgans in a conversation on data related to genetic testing, PARP inhibitors, and the data we saw come out of GU ASCO with the PROpel and MAGNITUDE trials and they discuss how this data impacts the use of PARP inhibitors in castrate-resistant prostate cancer (CRPC). Drs. Castro, Mateo, and Morgans discuss this data in terms of next-generation sequencing...
|
